Testimony Before the FDA’s Anesthetic and Analgesic Drug Products Advisory Committee Regarding Sublingual Sufentanil Tablets

View as PDF

In testimony before a meeting of the Food and Drug Administration’s (FDA’s) Anesthetic and Analgesic Drug Products Advisory Committee, Public Citizen urged the committee to recommend that the FDA reject new drug application submitted by AcelRx Pharmaceuticals for sufentanil sublingual tablets because the drug is a dangerous, high potency opioid that does not provide any unique advantages over currently available opioids, but does pose unique risks.

See Public Citizen’s other work on sufentanil tablets.

See Public Citizen’s other work on opioid drug issues.